Last edition
News about "pulmonary arterial hypertension "
Gossamer Bio Submits First NDA for Seralutinib in PAH
Gossamer Bio has filed an NDA for seralutinib, supported by Phase 3 PROSERA and Phase 2 TORREY study data.
Pulmonary Arterial Hypertension | 25/09/2026 | By News Bureau
FDA Updates Winrevair Label With Phase 3 HYPERION Data
Merck’s Winrevair label has been updated by the US FDA to include data from the Phase 3 HYPERION trial in recently diagnosed adults with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension | 23/09/2026 | By News Bureau | 110
WINREVAIR from Merck Gains Updated FDA Indication for Pulmonary Arterial Hypertension
Adding WINREVAIR from Merck to background PAH therapy improved exercise capacity and WHO Functional Class (FC), and reduced the risk of clinical worsening events, including hospitalisation for PAH, lung transplantation and death.
Pulmonary Arterial Hypertension | 29/10/2025 | By Dineshwori | 423
Corsair Pharma Collaborates with InstantGMP to Enhance Quality for Clinical Trials
Corsair Pharma is revolutionizing pulmonary arterial hypertension (PAH) treatment with its first product candidate: a prodrug of treprostinil delivered via a proprietary transdermal patch.
Pulmonary Arterial Hypertension | 30/01/2025 | By Aishwarya | 404
Alembic Pharma Gets USFDA Tentative Approval for Selexipag for Injection
Alembic Pharmaceuticals has secured tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Selexipag for Injection, 1,800 mcg/vial.
Pulmonary Arterial Hypertension | 15/07/2024 | By Aishwarya | 984
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy